Related Experiment Video
Updated: Jun 4, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Recent insights into drug resistance in ovarian cancer
1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA.
Abstract:
Ovarian cancer, as used in this review on drug resistance, applies to the study of the problem in those malignant tumors which arise from the modified peritoneal mesothelial cells, which cover the ovarian surface. These tumors are, by far, the most common malignancies of the ovary and display a remarkable range of histological features, which generally recapitulate those of the endocervix, endometrium, or Fallopian tube to which the ovarian surface epithelium is embryologically related. Of direct relevance to the issue of chemotherapeutic responsiveness is the fact that, stage for stage, some of these tumor subtypes carry a worse prognosis. The need for chemotherapy in ovarian cancer arises because this disease produces vague symptoms that occur only after it has spread from the confines of the ovary to the surfaces of the peritoneal cavity. At this stage, surgery rarely can eliminate all apparent disease, and even in those cases, experience shows that the disease will recur with high probability. This makes it obvious that residual microscopic disease remained after surgery. Hence, the majority of ovarian cancer patients require chemotherapy and its effective use has proved a tremendous challenge as evidenced by the approximately 14,000 deaths from this disease in the United States in 1997.
Insights
Ovarian cancer drug resistance is a major challenge, as chemotherapy is crucial for most patients due to late-stage diagnosis and surgical limitations. Understanding resistance mechanisms is key to improving patient outcomes.
Area of Science:
- Oncology
- Gynecologic Oncology
- Cancer Biology
Background:
- Ovarian cancer comprises malignant tumors originating from peritoneal mesothelial cells covering the ovarian surface.
- These tumors exhibit diverse histological features, often mirroring those of the endocervix, endometrium, or Fallopian tube.
- Certain ovarian cancer subtypes present a worse prognosis even at the same stage.
Purpose of the Study:
- To review the challenges of drug resistance in ovarian cancer.
- To highlight the critical role of chemotherapy in managing advanced-stage disease.
- To underscore the need for effective chemotherapeutic strategies given high recurrence rates.
Main Methods:
- This review synthesizes existing literature on ovarian cancer and drug resistance.
- It examines the origins and histological classifications of ovarian malignancies.
- The study focuses on the implications of disease spread and surgical outcomes on treatment efficacy.
Main Results:
- Ovarian cancer often presents with vague symptoms, leading to widespread peritoneal metastasis at diagnosis.
- Surgery is rarely curative, with a high probability of disease recurrence due to residual microscopic disease.
- Chemotherapy is a necessity for the majority of patients, but its effectiveness is significantly challenged by drug resistance.
Conclusions:
- The high mortality rate of ovarian cancer, exemplified by 14,000 US deaths in 1997, underscores the limitations of current treatments.
- Drug resistance in ovarian cancer necessitates further research into novel therapeutic approaches.
- Improving chemotherapy responsiveness is critical for enhancing survival rates in ovarian cancer patients.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers